Once again, it’s interesting that TD only parrots the plaintiffs’ claims and conveniently ignores RedHawk’s counter-claims.
Yes, RedHawk agreed to purchase certain needle technology from a group in South Africa through a commission. But if you actually read all the filings, you’d see the other side breached the deal by failing to deliver the required drawings and tooling. That failure forced RedHawk to spend hundreds of thousands of dollars abandoning the to-be-acquired tech and developing its own proprietary (now patented) technology.
Market Data 
Markets 
AI
